Abstract #806367: The Efficacy of Once-Weekly Subcutaneous Semaglutide is Comparable in Subjects with Type 2 Diabetes Aged < 65 Years and ≥ 65 Years: A Post Hoc Analysis of Sustain 1-5 and 7-10